The unique capabilities of MEAs to provide functional measurements of network activity, including spontaneous activity, evoked activity, and responses to pharmacological challenges, therefore offers an advantage over other potential screening approaches that rely on biochemical or structural endpoints.
1Robinette BL et al., (2011) Front Neuroeng 4; 1-9
Cell Type | Primary rat cortical neurons |
---|---|
Analysis Platform | Maestro 48-well MEA system (Axion BioSystems) |
Test Article Concentrations | Four concentrations in triplicate (dependent on customer requirements) |
Quality Controls | Negative control: 0.2% DMSO (vehicle) Positive controls: picrotoxin and domoic acid (at single concentration) |
Data Delivery | Firing rate (spikes/second) Burst rate (bursts/second) Number of spikes in burst Percent of isolated spikes Coefficient of variation (CV) of the inter-spike intervals (ISI) Burst duration Normalized IQR (inter-quartile range) burst duration Interburst interval Mean ISI-distance (measure of synchrony) Normalized Median Absolute Deviation (MAD) burst spike number Median ISI/Mean ISI |
The spontaneous spike activity is recorded in rat cortical neurons using Axion Biosystems microelectrode array Maestro platform. The spike train data is extracted from baseline and post dose measurements and converted to numerical values using a custom Matlab script to characterize firing and burst organization. The negative control 0.2% DMSO (vehicle) caused no change in activity, burst characteristics or synchrony. A distinct pattern of change affecting spike activity, burst characteristics and synchrony is observed with GABAA antagonists picrotoxin and gabazine. A different but significant pattern of activity can be seen with other proconvulsant toxins such as strychnine, a glycine receptor antagonist. Meanwhile complete abolishment of spike activity is observed with the neurotoxin, domoic acid.
Five representative electrodes out of the 16 electrodes in a well are shown over a 150 sec time span. The recorded spike activity of rat cortical neurons is represented by the raster plots which illustrate the structure of typical baseline spike activity for a well compared to its structure following a 10µM dose with the GABAA antagonist picrotoxin. The qualitative visual differences in the dynamics of the spike train are quantified through computation of the spike train features as seen in Figure 2.
Compound | Chemical class | Neurological effect in vivo | eCiphr®Neuro |
---|---|---|---|
0.2% DMSO | Vehicle | None | No effect |
Gabazine | GABAA antagonist | Seizurogenic2 | Seizurogenic |
Bicuculline | GABAA antagonist | Seizurogenic2 | Seizurogenic |
Picrotoxin | GABAA antagonist | Seizurogenic3 | Seizurogenic |
Pentylenetetrazole (PTZ) | GABAA antagonist | Seizurogenic4 | Seizurogenic |
Tutin | GABAA antagonist | Seizurogenic5 | Seizurogenic |
GABA | GABAA agonist | Decreases neural activity6 | Decreased activity |
Tetrodotoxin | Sodium channel blocker | Neurotoxic7 | Neurotoxic |
Aminopyridine | Potassium channel blocker | Seizurogenic8 | Seizurogenic |
Domoic Acid | Glutamate signalling | Neurotoxic9 | Neurotoxic |
L-Glutamate | Glutamate agonist | Increases neural activity10 | Increased activity |
Strychnine | Glycine receptor antagonist | Seizurogenic11 | Seizurogenic |
Acetaminophen | NSAID | None | No effect |
Ibuprofen | NSAID | None | No effect |
A number of compounds with a range of neurological effects were tested in the eCiphr®Neuro assay using rat cortical neurons. A good correlation was seen with drugs tested in this in vitro assay with their known in vivo effects. Different patterns of change affecting spike activity, burst characteristics and synchrony are observed in GABAA antagonists and other proconvulsants as illustrated in Figure 2.
1 Robinette BL et al, (2011) Front Neuroeng 4; Article 1
2 Margineau DG and Wülfert E (1997) Br J Pharmacol 122; 1146-1150
3 Mackenzie L et al, (2002) Clin Neurophysiol 113(4); 586-596
4 Ono J et al, (1990) Funct Neurol 5(4); 345-352
5 Fuentealba J et al, (2011) Neuropharmacology 60; 453-459
6 Levy LM and Degnan AJ, (2013) Am J Neuroradiol 34(2); 259-265
7 Hwang DF and Noguchi T (2007) Adv Food Nutr Res 52; 141-236
8 Peña F and Tapia R (2000) Neuroscience 101(3); 547-561
9 Pulido OM (2008) Mar Drugs 6(2); 180-219
10 Hankir MK et al, (2012) Neuroimage 59(2); 968-978
11 Kehne JH et al, (1992) Br J Pharmacol 106(4); 910-916
Learn more about toxicology in our popular Mechanisms of Drug-Induced Toxicity guide
Telephone:
Europe: +44 (0)1625 505100
North America (East Coast): +1-888-297-7683
Email:
info@evotec.eu